Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
18 studies found for:    tak-875
Show Display Options
Rank Status Study
1 Completed Pharmacokinetics and Pharmacodynamics of TAK-875 in Subjects With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Intervention: Drug: TAK-875
2 Terminated Study of TAK-875 in Adults With Type 2 Diabetes and Cardiovascular Disease or Risk Factors for Cardiovascular Disease
Conditions: Type 2 Diabetes;   Cardiovascular Disease
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo
3 Terminated Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo
4 Completed TAK-875 Glimepiride Drug-Interaction Study
Condition: Pharmacokinetics
Intervention: Drug: TAK-875 and Glimepiride
5 Terminated Fasiglifam 25 mg BID vs 50 mg QD
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Fasiglifam;   Drug: Placebo to fasiglifam
6 Terminated TAK-875 (Fasiglifam) in Combination With Sitagliptin in Adults With Type 2 Diabetes
Condition: Diabetes
Interventions: Drug: Placebo;   Drug: TAK-875
7 Terminated Efficacy and Safety of TAK-875 Compared to Glimepiride When Used With Metformin in Participants With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875;   Drug: Glimepiride
8 Terminated Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo;   Drug: Glimepiride
9 Terminated Comparison of TAK-875 With Sitagliptin When Used in Combination With Metformin in Patients With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875;   Drug: TAK-875 Placebo;   Drug: Sitagliptin;   Drug: Sitagliptin Placebo;   Drug: Metformin
10 Completed Efficacy and Safety of TAK-875 in Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: TAK-875;   Drug: Glimepiride;   Drug: Placebo
11 Withdrawn Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis
Conditions: Type 2 Diabetes Mellitus;   Chronic Kidney Disease
Interventions: Drug: Fasiglifam;   Drug: Placebo;   Drug: Antihyperglycemic therapy
12 Completed Efficacy and Safety of TAK-875 in Combination With Sitagliptin in Participants With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: TAK-875;   Drug: Sitagliptin;   Drug: TAK-875 and Sitagliptin
13 Terminated Comparison of TAK-875 to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes
Condition: Glycemic Control
Interventions: Drug: TAK-875;   Drug: Sitagliptin;   Drug: Placebo
14 Completed Comparison of TAK-875 With Placebo in Participants With Type 2 Diabetes
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo;   Drug: TAK-875
15 Completed Open-label Study of TAK-875
Condition: Diabetes Mellitus
Intervention: Drug: TAK-875
16 Completed Long-term Study of TAK-875
Condition: Diabetes Mellitus
Intervention: Drug: TAK-875
17 Completed Double Blind Comparative Study of TAK-875
Condition: Diabetic Patients
Interventions: Drug: TAK-875;   Drug: Glimepiride;   Drug: Placebo
18 Completed Double-blind Comparative Study of TAK-875
Condition: Diabetes Mellitus
Interventions: Drug: TAK-875;   Drug: Placebo

Indicates status has not been verified in more than two years